December 21, 2017

Prolong Completes Enrolling Patients in Phase 2 Trial of Sickle Cell Disease Therapy Sanguinate

Prolong Pharmaceuticals has completed enrolling patients in an ongoing Phase 2 clinical trial of Sanguinate, a treatment for the painful blocked blood vessel episodes that occur in sickle cell disease. ... Read more

May 4, 2017

Prolong Pharma’s Sanguinate Shows Promise in Reverting Shape of Red Blood Cells in SCD

Prolong Pharmaceuticals’ investigational drug for treatment of sickle cell disease (SCD)-associated complications, Sanguinate, showed promising results in patients experiencing vaso-occlusive crisis (VOC). According to the research study, “SANGUINATE Returns RBCs ... Read more

Pin It on Pinterest